ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Gastroenterology · Lancet Gastroenterol Hepatol · 2026-07-15

In 698 adults with MASH and F2–F4c fibrosis, weekly zalfermin 30 mg plus semaglutide 2·4 mg did not significantly improve fibrosis without MASH worsening at 52 weeks vs placebo (24% vs 16%; p=0·19); semaglutide alone was nominally better (30%).

RCTn = 698
Loomba et al. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
Diabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-06-07

Phase 3 RCT in 2713 adults with type 2 diabetes and BMI ≥25 on metformin: cagrilintide-semaglutide (2.4 mg each) vs semaglutide 2.4 mg reduced HbA1c more at 68 weeks (-1.91 vs -1.75 points; difference -0.16). Adverse events 86.9% vs 81.2%.

RCTn = 2,713
Buse et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Diabetes and endocrinology · Lancet · 2026-06-07

In 274 adults with type 2 diabetes on basal insulin, weekly cagrilintide-semaglutide (2·4 mg or 1·0 mg each) cut HbA1c by 2·33% and 2·10% vs 0·66% with placebo at 40 weeks (differences -1·68 and -1·44 points); weight fell 10-12%, no severe hypoglycaemia.

RCTn = 274
Rosenstock et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Diabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-04-17

In 331 adults with overweight or obesity in Japan and Taiwan, cagrilintide-semaglutide reduced bodyweight by 18.4% vs 11.9% with semaglutide alone at 68 weeks (difference -6.5 points); gastrointestinal adverse events 53% vs 51%.

RCTn = 331
Yamauchi et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.